Nukkleus Inc. Updates Principal Office Address in 8-K Filing

TL;DR

**Nukkleus Inc. updated its main office address and confirmed Nasdaq listing in a new 8-K.**

AI Summary

Nukkleus Inc. filed an 8-K on January 11, 2024, reporting an event that occurred on January 5, 2024. The filing updates the company's principal executive offices to 525 Washington Blvd, Jersey City, New Jersey 07310, and confirms its common stock (NUKK) is registered on The Nasdaq Stock Market LLC. This matters to investors because it provides updated contact information and confirms the listing of its securities, which are basic but essential details for due diligence.

Why It Matters

This filing provides updated administrative information for Nukkleus Inc., including its new principal executive office address and confirmation of its Nasdaq listing, which is important for investor records and transparency.

Risk Assessment

Risk Level: low — This filing is administrative in nature, updating contact information and confirming existing listings, posing minimal risk to investors.

Analyst Insight

Investors should update their records with the new principal executive office address for Nukkleus Inc. and note the confirmation of its Nasdaq listing, though this filing does not suggest any immediate trading action.

Key Numbers

• $0.0001 — Par value per share (Par value of Nukkleus Inc.'s common stock)

Key Players & Entities

• Nukkleus Inc. (company) — the registrant filing the 8-K
• The Nasdaq Stock Market LLC (company) — the exchange where Nukkleus Inc.'s common stock is registered
• January 5, 2024 (date) — date of the earliest event reported
• January 11, 2024 (date) — date the 8-K was filed
• 525 Washington Blvd, Jersey City, New Jersey 07310 (address) — new principal executive offices of Nukkleus Inc.
• $0.0001 (dollar_amount) — par value per share of common stock

FAQ

Key Financial Figures

• $0.0001 — ge on which registered Common Stock, $0.0001 par value per share NUKK The Nasdaq
• $11.50 — sable for one Share of Common Stock for $11.50 per share NUKKW The Nasdaq Stock Ma

Filing Documents

• ea191534-8k_nukkleus.htm (8-K) — 29KB
• 0001213900-24-003033.txt ( ) — 241KB
• nukk-20240105.xsd (EX-101.SCH) — 4KB
• nukk-20240105_def.xml (EX-101.DEF) — 26KB
• nukk-20240105_lab.xml (EX-101.LAB) — 36KB
• nukk-20240105_pre.xml (EX-101.PRE) — 25KB
• ea191534-8k_nukkleus_htm.xml (XML) — 5KB

01 Other Events

Item 8.01 Other Events. Nasdaq Compliance On January 5, 2024, Nukkleus Inc. (the "Company") received a written notice (the "Notice") from the Office of General Counsel of The Nasdaq Stock Market LLC ("Nasdaq") that Nasdaq had determined that the Company's prior deficiency under Nasdaq Listing rules had been cured in connection with the Company's business combination that took place on December 22, 2023. The Company's securities will continue to be listed and traded on Nasdaq. As previously reported in a Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on December 15, 2023, the Company received a written notice from the Nasdaq Listing Qualifications Department of Nasdaq on December 11, 2023, indicating that the Company was not in compliance with Listing Rule 5550(a)(3), which required the Company to have at least 300 public holders for continued listing on the Nasdaq Capital Market. 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Nukkleus Inc. (Registrant) Dated: January 11, 2024 By: /s/ Emil Assentato Name: Emil Assentato Title: Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR